ArriVent Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset

Arrivent Biopharma

related news
Pfizer Ventures gets behind OTR Therapeutics’s $100M series A to boost R&D hub’s capability

Fierce Biotech

December 05 2025
Kailera Therapeutics Announces $600 Million Series B Financing to Further Advance Pipeline of Next-Generation Therapies for the Treatment of Obesity

Kailera

October 14 2025

Get In Touch

Contact Us